VISITING SPEAKERS PROGRAM IN ONCOLOGY
2015-2016
The McGill Continuing Professional Development Office has made available, webcasts of the presentations.

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Date(s)</th>
<th>Institution</th>
<th>Title(s) of Presentation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Philip McCarthy</td>
<td>September 9-10</td>
<td>Roswell Park Cancer Institute of Buffalo USA</td>
<td>• Treatment Approach for the Transplant Eligible Multiple Myeloma Patient: Update and Controversies</td>
</tr>
<tr>
<td>Dr. Barbara Melosky</td>
<td>September 16-17</td>
<td>University of British Columbia, British Columbia Cancer Agency, Canada Canada</td>
<td>• Neuroendocrine Tumors of the Lung: State of the Art</td>
</tr>
<tr>
<td>Dr. Steven Chmura</td>
<td>September 23-24</td>
<td>University of Chicago USA</td>
<td>• The Role of Ablative Radiotherapy, Stereotactic Body Radiosurgery (SBRT), in Oligometastatic disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The Clinical and Scientific Basis for Limited or Oligometastatic Disease in Clinical Trials Design</td>
</tr>
<tr>
<td>Dr. Maria Victoria Mateos</td>
<td>October 7-8</td>
<td>University Hospital of Salamanca Spain</td>
<td>• The Evolving Treatment Landscape in Multiple Myeloma: New Therapies</td>
</tr>
<tr>
<td>Pr. Eric Raymond</td>
<td>October 14-15</td>
<td>Centre Hospitalier Universitaire Vaudois University of Lausanne (UNIL-CHUV), Switzerland</td>
<td>• Tumeur neuroendocrine du pancréas: Options de traitement en 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pancreatic NETs: Current Challenges and Advances</td>
</tr>
<tr>
<td>Dr. David Steensma</td>
<td>October 28-29</td>
<td>Harvard Medical School, Dana-Farber Cancer Institute, Boston USA</td>
<td>• Practical Case-based Discussion of the Management of MDS</td>
</tr>
<tr>
<td>Pr. Christophe Tournigand</td>
<td>November 11-12</td>
<td>Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, France</td>
<td>• Prise en charge du cancer colorectal métastatique (CCRm)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Strategies for Optimizing Treatment for Metastatic Colorectal Cancer Patients (mCRC)</td>
</tr>
<tr>
<td>Dr. Guy H. Jerusalem</td>
<td>December 2</td>
<td>Breast Clinic, Sart-Tilman University Hospital, University of Liège Belgium Belgium</td>
<td>• Clinical Update: Metastatic Breast Cancer</td>
</tr>
<tr>
<td>Name</td>
<td>Date</td>
<td>Location</td>
<td>Topic</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dr. Jacqueline C. Barrientos</td>
<td>April 20-21</td>
<td>New Hyde Park, Hofstra Northwell School of Medicine, New York USA</td>
<td>• The Treatment of Relapsed/Refractory CLL with Novel Agents</td>
</tr>
<tr>
<td>Dr. Jean-Yves Douillard</td>
<td>April 26-29</td>
<td>Université de Nantes, Institut de Cancérologie René Gauducheau FRANCE</td>
<td>• Evaluating 1st Line Strategies for RAS wt Metastatic Colorectal Patients</td>
</tr>
<tr>
<td>Dr. Scott North</td>
<td>May 11-12</td>
<td>University of Alberta, Cross Cancer Institute CANADA</td>
<td>• Improving Outcomes in Advanced Bladder Cancer Through Multidisciplinary Care</td>
</tr>
<tr>
<td>Dr. Christine Chen</td>
<td>June 29</td>
<td>University of Toronto, Princess Margaret Cancer Centre University Health Network (UHN) CANADA</td>
<td>• New Perspectives and Emerging Novel Agents in the Treatment of Waldenström's Macroglobulinemia in Canada</td>
</tr>
</tbody>
</table>
Dr Philip McCarthy
Professor of Oncology and Director
Blood and Marrow Transplant Center
Department of Medicine
Roswell Park Cancer Institute de Buffalo, NY

“Treatment approach for the transplant eligible multiple myeloma patient, update and controversies”

Wednesday, September 9, 2015

GLEN Site
Room D 02.1312
8:30 to 9:30

Learning Objectives

- What is the role of maintenance post transplant in multiple myeloma?
- Which agent to use in that setting?
- Do all patients benefit from this approach?
- Views on consolidation vs maintenance for both?

Hôpital Maisonneuve-Rosemont
Room 0-80
Videoconference: https://www.irisreservation.ca
12:00 to 13:00

- Opinion on one vs two transplants for the transplant eligible myeloma patient
- Opinion on allogeneic transplant in myeloma
- What should be the decision regarding maintenance for the patient with a CR post transplant?
- What is the optimal TFI (treatment free interval) for directing the patient towards a second transplant?
- Is thromboprophylaxis appropriate for maintenance treatment?

Hôpital Notre-Dame (Pavillon Deschamps)
Room I-1176-2
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510
17:00 to 18:00

- Is maintenance necessary for all patients or are some benefiting more than others?
- Discuss different protocols on maintenance with their advantages/disadvantages
- How do you manage side effects and adjust therapy for maintenance patients?
- How do you follow up risks on secondary malignancy?

Thursday, September 10, 2015

Jewish General Hospital
Room E711
Videoconference: http://telesantemcgill.ca/
12:30 to 13:30

- What is the best approach for the treatment of a multiple myeloma patient eligible for transplant?
- What are the latest data and recommendation regarding the use of an agent in maintenance after transplant?
- Which patient is susceptible to benefit from this approach (Which agent? Which patient?)
- How does the general approach for the transplant eligible patient modified for the high risk cytogenetic patient?
- What treatment is recommended following maintenance?

Hôpital du Sacré-Cœur de Montréal
Salle G-4115
Videoconference: https://www.irisreservation.ca
15:00 to 16:00

- Advantages and disadvantages of maintenance treatment
- Do all patients benefit from this approach?
- How do you manage a patient on maintenance therapy?
Dr Barbara Melosky
Associate Professor of Medicine,
University of British Columbia
Medical Oncologist,
British Columbia Cancer Agency

“Neuroendocrine Tumors of the Lung: State of the Art”

Wednesday, September 16, 2015

GLEN Site
Room D 02.4250
8:00 to 9:00

Jewish General Hospital
Room E711
12:00 to 13:00
Videoconference: http://telesantemcgill.ca/tswp/event-details.asp?id=29188

Hôpital Notre-Dame (Pavillon Deschamps)
Room I-1176-2
17:00 to 18:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Thursday, September 17, 2015

Hôpital du Sacré-Cœur de Montréal
Salle G-4115
15:00 to 16:00
Videoconference: https://www.irisreservation.ca

Learning Objectives

• Understand the classification and differences of low, intermediate and high grade neuroendocrine tumors of the lung
• Review current treatment algorithms for neuroendocrine thoracic tumors
• Explore new treatment options

This event is approved for up to 1 credit by the Office for Continuing Health Professional Education (CHPE). The Office for CHPE, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Schools. This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through a reciprocal agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Office for CHPE, Faculty of Medicine, McGill University designates this activity for AMA PRA Category 1 credit up to the maximum number of credit hours noted above. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information or a complete description of these events, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp
Dr Steven Chmura
Associate Professor
Radiation and Cellular Oncology
The University of Chicago

Wednesday, September 23, 2015

“The role of ablative radiotherapy, stereotactic body radiosurgery (SBRT), in oligometastatic disease”

17:00 h to 18:00 h - Hôpital Notre-Dame Auditorium Deschamps

Learning Objectives
• To improve patients care with oligometastatic disease
• To review new approaches for the treatment of oligometastatic patient
• To update options radiation therapy options in the treatment of oligometastatic patient
• To discuss the role of stereotactic body radiosurgery (SBRT) in the management of oligometastatic disease

Thursday, September 24, 2015

“The clinical and scientific basis for limited or oligometastatic disease in clinical trials design”

12:00 to 13:00 – Juif General Hospital Room G18.102 Radiation Oncology Department
Visioconference : http://telesantemcgill.ca/tswp/?page_id=1371&id=28800
14:00 to 16:00 - Meet the professor - Room G18.102 Radiation Oncology Department

Learning Objectives
• Describe the clinical and scientific basis for limited or oligometastatic disease
• Discuss initial ablative series with surgery or radiotherapy suggesting improved long term outcomes
• Discuss clearly defined roles for resection of limited disease
• Discuss the design and rationale for NRG BR001 – Why is a phase I trial needed for multiple metastases and SBRT?
• Discuss the Phase II/III Design of NRG BR002
• What can current and future science tell us about who is truly “Oligometastatic” vs “OligoVisible”

This event is approved for up to 1 credit by the Office for Continuing Health Professional Education (CHPE). The Office for CHPE, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Schools. This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through a reciprocal agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Office for CHPE, Faculty of Medicine, McGill University designates this activity for AMA PRA Category 1 credit up to the maximum number of credit hours noted above. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information or a complete description of these events, please visit our website at: http://wwwmedicine.mcgill.ca/medicine/speakers/speakers_visiting_speakers.asp
Dr Maria Victoria Mateos, M.D., Ph.D
Director - Myeloma Unit
Associate Professor and Consultant Physician
Haematology Department
University Hospital of Salamanca, Spain
Member of the PETHEMA board and the International Myeloma Working Group

“The Evolving Treatment Landscape in Multiple Myeloma: New Therapies”

Wednesday, October 7, 2015
GLEN Site
Room D 02.1312
8:30 to 9:30
Videoconference:
http://telesantemcgill.ca
nathalie.huard.chum@ssss.gouv.qc.ca
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Hôpital Maisonneuve-Rosemont
Room 0-80 (Pavillon Marcel Lamoureux)
12:00 to 13:00
Videoconference:
https://www.irisreservation.ca
nathalie.huard.chum@ssss.gouv.qc.ca

Thursday, October 8, 2015
Jewish General Hospital
Room E-711
12:30 to 13:30
Videoconference:
http://telesantemcgill.ca
nathalie.huard.chum@ssss.gouv.qc.ca

Learning Objectives
After having participated in this conference, participants will be able to:
• Recognize the unmet needs in the treatment of Multiple Myeloma (MM)
• Identify the upcoming role of targeted therapies in the treatment of MM
• Apply to their own practice insights shared through the review of patient cases

This event is approved for up to 1 credit by the Office for Continuing Health Professional Education (CHPE). The Office for CHPE, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Schools. This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through a reciprocal agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Office for CHPE, Faculty of Medicine, McGill University designates this activity for AMA PRA Category 1 credit up to the maximum number of credit hours noted above. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information or a complete description of these events, please visit our website at:
http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting speakers.asp
This event is approved for up to 1 credit by the Office for Continuing Health Professional Education (CHPE). The Office for CHPE, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Schools. This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through a reciprocal agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Office for CHPE, Faculty of Medicine, McGill University designates this activity for AMA PRA Category 1 credit up to the maximum number of credit hours noted above. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information or a complete description of these events, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting speakers.asp

**Pr Eric Raymond**

Chef de Service  
Medical Oncology Service  
Oncology Unit  
Centre Hospitalier Universitaire Vaudois  
University of Lausanne (UNIL-CHUV)

---

**“Tumeur neuroendocrine du pancréas : Options de traitement en 2015”**  
FRENCH TALK

**Learning objectives**  
Revoir la classification, les symptômes et les défis reliés au diagnostic  
Présenter l’algorithme de traitement 2015 et le rôle des thérapies ciblées  
Discuter des perspectives futures de traitement

**Wednesday, October 14, 2015**

**Hôpital Cité-de-la-santé de Laval** – Room GS-011  
8:00 to 9:00  
Visio: ast-jacques.csssl@ssss.gouv.qc.ca

**Hôpital Notre-Dame** – Amphithéâtre Deschamps  
17:00 to 18:00  
Live onl Web! [www.vpsolution.tv/vspo](http://www.vpsolution.tv/vspo)  
Problems/Questions: 514 813-4510

**Thursday, October 15, 2015**

**Hôpital du Sacré-Cœur de Montréal**  
Room G-4115  
15:00 to 16:00

---

**“Pancreatic NETs: Current Challenges and Advances”**  
ENGLISH TALK

**Learning objectives**  
Present the challenges in the diagnosis of pNETS  
Describe how should clinicians approach treatment and sequence therapies  
Discuss the management of the most common toxicities with targeted agents  
Outline the next steps in research for pNETs

**Wednesday, October 14, 2015**

**Jewish General Hospital** - Room E711  
12:00 to 13:00  
Live onl Web! [www.vpsolution.tv/vspo](http://www.vpsolution.tv/vspo)  
Problems/Questions: 514 813-4510  
Visio: [http://telesantemcgill.ca/tswp/?page_id=1371&id=30004](http://telesantemcgill.ca/tswp/?page_id=1371&id=30004)

**Thursday, October 15, 2015**

**Glen Site, Research Centre** – Room EM1.3509  
8:00 to 9:00  
Visio: [http://telesantemcgill.ca/tswp/?page_id=1371&id=30005](http://telesantemcgill.ca/tswp/?page_id=1371&id=30005)
Dr David Steensma
Associate Professor,
Medicine Harvard Medical School
Faculty member,
Adult Leukemia Program
Dana-Farber Cancer Institute, Boston

“Emerging Evidence in MDS”

Wednesday, October 28, 2015
GLEN Site – Room D02.1312
8:30 to 9:30
Hôpital Maisonneuve-Rosemont - Room 080
12:00 to 13:00
Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00
www.vpsolution.tv/vspo
Problems/Questions:
514 813-4510

Thursday, October 29, 2015
Jewish General Hospital – Room E-7
12:30 to 13:30

Learning objectives
• To discuss innovative and emerging approaches to the current management of MDS patients (treatment choice, dose and schedule considerations, outlook and management of patients relapsed or refractory to hypomethylating agents, prospects for combination therapies)
• To provide insight into genetic testing in cases of suspected MDS including the frequency of mutations, the prognostic value of mutations and the utility of genetic testing in therapeutic decision making
• To provide clinicians with insight into the future landscape for the management of MDS patients

“Practical Case Based Discussion of the Management of MDS”

Thursday, October 29, 2015
Hôpital du Sacré-Cœur de Montréal
Room G-4115
15:00 to 16:00

Learning objectives
• To provide clinicians with an overview of the current therapeutic options for treating MDS (lower and higher risk)
• To provide clinicians with practical guidance through case based discussion of the optimal utilization of current therapeutic options (choosing the appropriate patients, managing comorbidities and early cycle adverse events, optimizing the duration of treatment)
• To provide clinicians with insight into the future landscape for the management of MDS patients

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaasnn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp
Pr Christophe Tournigand, M.D., PhD
Head of the medical oncology department,
Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris
Professor, Université Paris-Est Créteil

**Wednesday, November 11, 2015**
Hôpital Notre-Dame
Amphithéâtre Deschamps

17:00 to 18:00
Live on the Web! [www.vpsolution.tv/vspo](http://www.vpsolution.tv/vspo)
Problems/Questions: 514 813-4510

**“Prise en charge du cancer colorectal métastatique (CCRm)”**
FRENCH TALK

**Learning objectives**
- Identifier des stratégies thérapeutiques pour les patients atteints de CCRm en fonction de leurs caractéristiques individuelles, de leurs préférences et du statut des biomarqueurs afin d'optimiser le traitement
- Évaluer les évidences cliniques de la thérapie d'entretien et de la poursuite de l'inhibition de l'angiogénèse dans le cancer colorectal métastatique

**Thursday, November 12, 2015**
MUCH - Glen Site
Room D 03.5039
Directions: Use the elevator D-04 or D05 and go to the 3rd floor. Turn left and go through the doors of the ICU indicated ACCESS RESTRICTED to authorized personnel only

12:00 to 13:00
Live on the Web! [www.vpsolution.tv/vspo](http://www.vpsolution.tv/vspo)
Problems/Questions: 514 813-4510

**“Strategies for Optimizing Treatment for Metastatic Colorectal Cancer patients (mCRC)”**
ENGLISH TALK

**Learning objectives**
- Identify therapeutic strategies for patients with mCRC based on their individual characteristics, their biomarker status and their preferences in order to optimize treatment
- Review the evidence for maintenance therapy in mCRC and for continued anti-VEGF inhibition

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website: [http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp](http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp)

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche
Dr Guy H. Jerusalem, MD, PhD
Head of Medical Oncology in the Department of Medicine
Director of the Breast Clinic, Sart-Tilman University Hospital
Professor in Medical Oncology, University of Liège in Belgium

“Clinical Update: Metastatic Breast Cancer”

Wednesday, December 2, 2015

Hôpital général du Lakeshore
Cafeteria conference room
(ENGLISH TALK)
8:00 à 9:00

Jewish General Hospital
Room E-711
(ENGLISH TALK)
12:00 à 13:00
Visioconference: http://telesantemcgill.ca
nathalie.huard@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps
(FRENCH TALK)
17:00 à 18:00
Live on the Web! www.vpsolution.tv/ppio
Problems/Questions: 514 813-4510

Learning Objectives
• To gain a better understanding endocrine resistance in HR+ advanced breast cancer and provide strategies to overcome it
• To understand the sequencing of treatment options for the different types of post-menopausal patients with ER+/HER2 negative advanced breast cancer
• To review best strategies for AE management, with oral targeted agents (BRAWO data)

This event has received an educational grant from:
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche
Dr Jacqueline C. Barrientos, MD
Hematologist, New Hyde Park
Assistant Professor, Hofstra Northwell School of Medicine
New York

“The Treatment of Relapsed/Refractory CLL with Novel Agents”

Wednesday, April 20, 2016
GLEN Site
Room D 02.1312
8:30 to 9:30
Videoconference: vspo@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps
(Room I-1176-2)
17:00 to 18:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Thursday, April 21, 2016
Hôpital du Sacré-Cœur de Montréal
Room C-5175
8:00 to 9:00

Jewish General Hospital
Room E-711
12:30 to 13:30
Videoconference: vspo@mcgill.ca

Learning Objectives
• Recognize the role of novel CLL agents in the treatment of relapsed/refractory Chronic Lymphocytic Leukemia (CLL)
• Determine how and when to use novel agents in the treatment of CLL
• Explore the clinical experience with novel agents in relapsed/refractory CLL treatment through the review of patients cases

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche
Dr Jean-Yves Douillard, MD, Ph.D.
Medical Oncologist Professor, Université de Nantes, France
Research and Medical Director, Institut de Cancérologie René Gauducheau

“Evaluating 1st Line Strategies for RAS wt Metastatic Colorectal Patients”

Learning Objectives

- Identify first-line options
- Assess the impact of depth of response and early tumor shrinkage on OS, PFS, resectability and quality of life
- Discuss hypotheses to define the best sequence

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting-speakers.asp

This program has received an educational grant from:
Asgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche
Dr Scott North
Professor & Division Director
Medical Oncology
Department of Oncology
University of Alberta
Cross Cancer Institute

“Improving Outcomes in Advanced Bladder Cancer Through Multidisciplinary Care”

Wednesday
May 11, 2016
12:00 to 13:00
GLEN Site
Room D02.4250
Visioconference:
vspl@mcgill.ca

Wednesday
May 11, 2016
17:00 to 18:00
Notre-Dame Hospital
Amphithéâtre Deschamps

Thursday
May 12, 2016
12:00 to 13:00
Charles Le Moyne Hospital
Room HN 106

Live on the Web:
www.vpsolution.tv/vspo
Problems/Questions:
514 813-4510

Learning Objectives

• Discuss standard of care issues in the multidisciplinary management of muscle-invasive bladder cancer with a special focus on logistical pearls to optimize care

• Identify the appropriate patient with locally advanced bladder cancer that may be treated by bladder sparing-surgery, including the option of chemoradiation

• Discuss new paradigms in the treatment of metastatic urothelial carcinoma in the era of emerging immunotherapy options

• What is the best chemotherapy radiosensitizer in cisplatin um fit and unfit patient?

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche

For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp
Dr Christine Chen, M.D.
Associate professor, 
University of Toronto 
Head of the Autologous Stem Cell Transplant program, 
Princess Margaret Cancer Centre 
University Health Network (UHN)

“New Perspectives and Emerging Novel Agents in the Treatment of Waldenström’s Macroglobulinemia in Canada”

Wednesday June 29, 2016
GLEN Site - MGH
Salle D.02.1312
8:30 to 9:30

Hôpital Maisonneuve-Rosemont
Room 10, 1st Floor (Pavillon JA DeSève)
12:00 to 13:00
Videoconference: vspo@mcgill.ca
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Hôpital Notre-Dame
Amphithéâtre Deschamps - I-1176
17:00 à 18:00

Learning Objectives
• To discuss the current treatment options and unmet needs for Canadian patients with Waldenström’s Macroglobulinemia
• To explore the role of targeted therapy in emerging treatment strategies for relapsed and refractory disease
• To share clinical experience with new agents for the treatment of Waldenström’s Macroglobulinemia and practical considerations to optimize patient outcomes

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche